I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Kanion Pharmaceutical released its 2024 annual report, stating that the company's operating revenue for 2024 is 3.898 billion yuan, a year-on-year decrease of 19.86%; the net profit attributable to shareholders of the listed company is 392 million yuan, a year-on-year decrease of 15.58%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses is 363 million yuan, a year-on-year decrease of 27.29%; the basic earnings per share is 0.68 yuan/share
According to the Zhitong Finance APP, Kanion Pharmaceutical (600557.SH) released its 2024 annual report, stating that the company's operating revenue for 2024 was 3.898 billion yuan, a year-on-year decrease of 19.86%; the net profit attributable to shareholders of the listed company was 392 million yuan, a year-on-year decrease of 15.58%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 363 million yuan, a year-on-year decrease of 27.29%; the basic earnings per share was 0.68 yuan/share